Phio submits FDA package for PH-762, plans Phase 2b study
Phio said it submitted a briefing package to the FDA for PH-762 and plans a Phase 2b neoadjuvant study after completing Phase 1b.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.